Latest News & Features
article
A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports. 7 April 2022
Europe
Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office. 5 April 2022
Generics
Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia. 5 April 2022
Big Pharma
Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet. 4 April 2022
Americas
The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa. 31 March 2022
Big Pharma
Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs. 31 March 2022
Medtech
Medical device companies have asked a US federal judge to eliminate an exemption that allows the bypassing of technological protections for copyrighted software if it is in service of using or repairing medical devices. 31 March 2022
Medtech
DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents. 29 March 2022
Big Pharma
ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday. 29 March 2022
Generics
Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD. 29 March 2022